On December 19, at the "2025 TVB Environmental, Social, and Governance (ESG) Awards Presentation Ceremony" held in Hong Kong, organized by TVB and co-organized by the Hong Kong Productivity Council, Sino Biopharmaceutical Limited (1177.HK) was honored with the "ESG Social Innovation Science and Technology Award" for its innovative practices in carbon neutrality strategy and climate risk governance. 

In recent years, the frequent occurrence of extreme weather and the trend of global warming are having a systematic and profound impact on global economic and social development. As a leading enterprise in China's pharmaceutical and healthcare industry, Sino Biopharmaceutical Limited is committed to building an environmentally friendly enterprise, persistently advancing a green and low-carbon transition. In early 2025, it was the first in China's pharmaceutical industry to release the "Carbon Neutrality Target and Pathway Plan", aiming to contribute to the industry's green transformation and the nation's dual carbon goals. This award represents a high level of recognition from authoritative media for Sino Biopharmaceutical Limited's efforts in driving green growth through technological innovation. 

To effectively implement the group's carbon neutrality plan and actively respond to the new ESG climate regulations of the Stock Exchange of Hong Kong Ltd., the Sino Biopharmaceutical Limited ESG Work Management Committee recently held the "2025 Special Meeting on Climate Risk and Carbon Neutrality Action". The meeting focused on three main agenda items: (1) Deliberating the establishment of the "Sino Biopharmaceutical Limited ESG Management Committee Climate Risk Management Special Committee" and concurrently releasing the "Working Charter of the Sino Biopharmaceutical Limited Climate Risk Special Committee"; (2) Reviewing and discussing the "Sino Biopharmaceutical Limited Carbon Neutrality Action First Phase Target and Implementation Plan", which aims to comprehensively promote low-carbon management practices across all areas on a five-year cycle to ensure the achievement of the 2030 carbon peak target; (3) Organizing a "Special Training on the Stock Exchange of Hong Kong Ltd.'s New Climate Governance Regulations" to ensure that committee members deeply understand the core requirements of the new regulations, accurately grasp climate risks and opportunities, and lay a solid capacity foundation for systematic and refined climate-related work. 

The meeting was chaired by Mr. Song Jin, Chairman of the Committee and Vice President in charge of ESG. Also in attendance were Mr. Tse Hsin, Executive Director, member of the Executive Directors Committee, and Senior Vice President of the Group, along with 12 full-time committee members from relevant departments including the Group's ESG, digitalization, supply chain, finance, compliance, human resources, legal, public affairs, and public relations. 

Climate change is a severe challenge faced by the entire world. Sino Biopharmaceutical Limited will be driven by the dual wheels of R&D innovation and low-carbon technology, guided by high-level ESG management. It will coordinate development and security, actively address climate challenges, seize opportunities in the low-carbon transition, and unswervingly follow a high-quality development path of stable operations, innovation, and green, low-carbon practices, continuing to fulfill its mission and responsibility as an industry leader.